Drugs / LY3322207
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03590860 | Jul 2018 → Jan 2019 | hypertensive disorder | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3322207 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03590860 ↗ |
| Route | Subcutaneous | “Administered by SC injection” NCT03590860 ↗ |